BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $653 | +60.0% | 24,750 | +4.2% | 0.00% | +100.0% |
| Q2 2023 | $408 | +3.6% | 23,750 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $394 | +117.7% | 23,750 | 0.0% | 0.00% | +100.0% |
| Q4 2022 | $181 | -99.9% | 23,750 | +19.0% | 0.00% | 0.0% |
| Q3 2022 | $198,000 | +9.4% | 19,950 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $181,000 | -10.4% | 19,950 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $202,000 | -39.3% | 19,950 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $333,000 | -71.3% | 19,950 | -19.4% | 0.00% | -66.7% |
| Q3 2021 | $1,160,000 | -9.2% | 24,750 | +18.1% | 0.01% | -14.3% |
| Q2 2021 | $1,277,000 | +8.2% | 20,950 | +9.4% | 0.01% | 0.0% |
| Q1 2021 | $1,180,000 | +22.0% | 19,150 | +40.8% | 0.01% | +16.7% |
| Q4 2020 | $967,000 | +89.6% | 13,600 | 0.0% | 0.01% | +50.0% |
| Q3 2020 | $510,000 | -42.4% | 13,600 | -50.0% | 0.00% | 0.0% |
| Q2 2020 | $886,000 | – | 27,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |